Wellbutrin SR Patent Cases: Did GSK Surrender Claims To Excipients?
Executive Summary
GlaxoSmithKline's patent infringement cases against Impax and Excel regarding Wellbutrin SR and Zyban appear to hinge on whether excipients used by the generic firms were "foreseeable.
You may also be interested in...
Impax/Teva Wellbutrin SR Generic Cleared To Launch By Court, FDA
Impax' bupropion sustained-release generic is cleared for launch following an appeals court ruling that the company does not infringe GlaxoSmithKline's Wellbutrin SR/Zyban patent
Watson Inventory Reserves Reflect Delayed Launch Of Wellbutrin SR Generics
Watson is taking an inventory reserve to account for the delayed launch of its "authorized" generic of GlaxoSmithKline's Wellbutrin SR (bupropion sustained-release)
Watson Inventory Reserves Reflect Delayed Launch Of Wellbutrin SR Generics
Watson is taking an inventory reserve to account for the delayed launch of its "authorized" generic of GlaxoSmithKline's Wellbutrin SR (bupropion sustained-release)